Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

Bookmark and Share
Published: 30 May 2015
Views: 4251
Dr Nicholas Turner - The Institute of Cancer Research, London, UK

Dr Turner talks to ecancertv at ASCO 2015 about the phase III registration study PALOMA-3, which reports that adding the investigational targeted agent palbociclib to standard hormonal therapy (fulvestrant) more than doubled the duration of disease control, delaying disease progression by roughly five months in women with previously treated, hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR /HER2-) advanced breast cancer.

Read the news article and watch the press conference for more.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.